Nov 15 (Reuters) - Precision BioSciences Inc :
* PRECISION BIOSCIENCES HIGHLIGHTS PRECLINICAL DATA AND OUTLINES DESIGN OF FIRST-IN-HUMAN CLINICAL TRIAL FOR PBGENE-HBV FOR TREATMENT OF CHRONIC HEPATITIS B
* PRECISION BIOSCIENCES INC - PBGENE-HBV DATA SUPPORT ADVANCEMENT INTO FIRST-IN-HUMAN STUDY
* PRECISION BIOSCIENCES INC - PHASE 1 TRIAL ELIMINATE-B TO ASSESS SAFETY AND EFFICACY
* PRECISION BIOSCIENCES INC - GLOBAL STUDY RECRUITING PATIENTS, U.S. IND EXPECTED IN 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.